| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | |
|---|---|---|---|---|
| Loss from operations | -3,382 | -1,513 | -1,932 | |
| Other income | - | 156 | - | |
| Unrealized gain on short-term investments | - | 0 | - | |
| Interest income | 36 | 38 | 32 | |
| Gain on settlement of vendor payable | - | 0 | 998 | |
| Change in fair value of warrant liability | -232 | 114 | -126 | |
| Total other income (expense), net | 268 | 80 | 1,156 | |
| Net loss | -3,114 | -1,433 | -776 | |
| Dividends on preferred stock | 144 | 85 | - | |
| Net loss attributable to common stockholders | -3,258 | -1,518 | - | |
| Net loss per share - basic | -0.83 | -0.55 | -0.33 | |
| Net loss per share - diluted | -0.83 | -0.55 | -0.33 | |
| Weighted average common shares outstanding - basic | 3,940,714 | 2,771,765 | 2,345,087 | |
| Weighted average common shares outstanding - diluted | 3,940,714 | 2,771,765 | 2,345,087 | |
GT Biopharma, Inc. (GTBP)
GT Biopharma, Inc. (GTBP)